Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
Cancer Medicine · 2024
DOI: 10.1002/cam4.7232 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Xiaoyan Han und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zh…. Hauptthemen laut MEDLINE: Multiple Myeloma, Thalidomide, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Comparative investigations evaluating the efficacy of pomalidomide‐based (Pom‐based) versus daratumumab‐based (Dara‐based) therapies in patients with relapsed/refractory multiple myeloma (RRMM) remain scarce, both in randomized controlled trials and real‐world studies.
Methods
This retrospective cohort study included 140 RRMM patients treated with Pom‐based or Dara‐based or a combination of pomalidomide and daratumumab (DPd) regimens in a Chinese tertiary hospital between December 2018 and July 2023.
Results
The overall response rates (ORR) for Pom‐based ( n = 48), Dara‐based ( n = 68), and DPd ( n = 24) groups were 57.8%, 84.6%, and 75.0%, respectively ( p = 0.007). At data cutoff on August 1, 2023, the median progression‐free survival (PFS) was 5.7 months (95% CI: 5.0–6.5) for the Pom‐based group, 10.5 months (5.2–15.8) for the Dara‐based group, and 6.7 months (4.0–9.3) for the DPd group ( p = 0.056). Multivariate analysis identified treatment regimens (Dara‐based vs. Pom‐based, DPd vs. Pom‐based) and Eastern Cooperative Oncology Group performance status (ECOG PS) as independent prognostic factors for PFS. In the subgroups of patients aged >65 years, with ECOG PS ≥2, lines of therapy ≥2, extramedullary disease or double‐refractory disease (refractory to both lenalidomide and proteasome inhibitors), the superiority of Dara‐based regimens over Pom‐based regimens was not evident. A higher incidence of infections was observed in patients receiving Dara‐based and DPd regimens (Pom‐based 39.6% vs. Dara‐based 64.7% vs. DPd 70.8%, p = 0.009).
Conclusions
In real‐world settings, Pom‐based, Dara‐based, and DPd therapies exhibited favorable efficacy in patients with RRMM. Dara‐based therapy yielded superior clinical response and PFS compared to Pom‐based therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
ORCID-Profile: Jingsong He, Yi Zhao, Zhen Cai
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Han, X., Jiang, X., He, J., Zheng, G., Xiong, Y., Wen, Y., Yang, Y., He, D., Chen, Q., Zhao, Y., Li, Y., Wu, W., & Cai, Z. (2024). Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China. Cancer Medicine. https://doi.org/10.1002/cam4.7232
Vancouver
Han X, Jiang X, He J, Zheng G, Xiong Y, Wen Y, et al. Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China. Cancer Medicine. 2024. doi:10.1002/cam4.7232
BibTeX
@article{Han2024,
author = {Han, Xiaoyan and Jiang, Xincheng and He, Jingsong and Zheng, Gaofeng and Xiong, Yaqin and Wen, Yanling and Yang, Yang and He, Donghua and Chen, Qingxiao and Zhao, Yi and Li, Yi and Wu, Wenjun and Cai, Zhen},
title = {Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7232}
}
EUVIMED